Phase 4 Oesophageal Cancer Trial, Recruiting NCT06420258 Sponsor: Fujian Provincial Hospital Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 4 Oesophageal Cancer Trial, Recruiting

NCT06420258
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose condition involves early-stage squamous cell cancer or high-grade abnormal cell growth (a pre-cancerous condition) located in the upper part of the food pipe (esophagus)
  • People whose scans and internal camera examinations show no signs that the cancer or abnormal cells have spread to nearby lymph nodes or other parts of the body
  • People who have been fully informed about the study and have agreed to take part by signing a consent form

Who may not be able to join:

  • People who have already received radiation therapy or chemotherapy before the planned surgical procedure (a procedure called endoscopic submucosal dissection, where tissue is removed using a camera and instrument passed down the throat)
  • People with serious other health conditions that would make the endoscopic submucosal dissection procedure unsuitable for them (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Wei Liang, MD, Fujian Provintial Hospital

Phone: +86 13599382136

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Fujian Provincial Hospital
Registry
ClinicalTrials.gov
Start date
1 October 2022
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

the rate of complete resection and postoperative stricture

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov